The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy

Authors

  • Angelina Tjokrowidjaja National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, Australia; ;Cancer Care Centre, St George Hospital, Kogarah, Australia
  • David Goldstein Translational Cancer Research Network, University of New South Wales, Sydney, Australia; ;Nelune Cancer Centre, Prince of Wales Hospital, Randwick, Australia
  • H. Malcolm Hudson National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, Australia; ;Department of Statistics, Macquarie University, Macquarie Park, Australia;
  • Sarah J. Lord National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, Australia; ;School of Medicine, The University of Notre Dame, Sydney, Australia
  • Val Gebski National Health and Medical Research Council Clinical Trials Centre, The University of Sydney, Sydney, Australia;
  • Stephen Clarke Sydney Medical School, The University of Sydney, Sydney, Australia

DOI:

https://doi.org/10.1080/0284186X.2019.1656342

Abstract

No abstract available

Downloads

Download data is not yet available.

Downloads

Additional Files

Published

2020-01-02

How to Cite

Tjokrowidjaja, A. ., Goldstein, D. ., Malcolm Hudson, H. ., Lord, S. J. ., Gebski, V. ., & Clarke, S. . (2020). The impact of neutrophil-lymphocyte ratio on risk reclassification of patients with advanced renal cell cancer to guide risk-directed therapy. Acta Oncologica, 59(1), 20–27. https://doi.org/10.1080/0284186X.2019.1656342

Issue

Vol. 59 No. 1 (2020): Acta Oncologica

Section

Articles